347 results on '"Berrien-Elliott, Melissa"'
Search Results
2. Induced CD8[alpha] identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation
3. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
4. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction
5. Allogeneic natural killer cell therapy
6. MicroRNA‐146a deficiency enhances host protection against murine cytomegalovirus.
7. Memory-like differentiation enhances NK cell responses against colorectal cancer.
8. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
9. A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells
10. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant
11. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
12. Memory-like natural killer cells for cancer immunotherapy
13. Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity
14. Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development
15. Anti-myeloma efficacy of BCMA CAR-iNKT is enhanced with a long-acting IL-7, rhIL7hyFc
16. MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells
17. Donor-Derived Memory-like NK Cells for the Treatment of Children and Young Adults with Relapsed AML Following Allo-HCT
18. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
19. Supplementary Figure S7 from Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer
20. Data from Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer
21. Supplementary Table S1 from Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer
22. Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer
23. Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses
24. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
25. S129: ADOPTIVELY INFUSED MEMORY-LIKE (ML) NATURAL KILLER (NK) CELLS ELICIT ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
26. T-BET and EOMES sustain mature human NK cell identity and antitumor function
27. Brief IL-12, IL-15, IL-18 activation drives the acquisition of two distinct memory-like NK cell states
28. Combined IL-12, IL-15 and IL-18 activation induces epigenetic changes in human NK cells during the memory-like state transition
29. CD8α identifies human NK cells with altered proliferation, metabolism, and IL-15 signaling
30. Supplementary Table 5 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
31. Data from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
32. Abstract 6418: xWU-NK-101 as salvage therapy post immune checkpoint blockade (ICB)
33. Supplementary Figure Legends from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
34. Supplementary Table 4 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
35. Supplementary Figures 1-8 and Tables 1-3 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
36. Data from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
37. Data from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
38. Supplementary Tables from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
39. Supplemental Figure S1 from Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
40. Supplementary Figure S4 from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
41. Supplementary Methods from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
42. Supplemental Methods from Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
43. Supplementary Methods from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
44. Data from Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
45. Supplementary Figures from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
46. Supplementary Figure S4 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
47. Table S1 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
48. Supplementary Table S2 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
49. Figure S3 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
50. Data from MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.